Cargando…

5mC regulator-mediated molecular subtypes depict the hallmarks of the tumor microenvironment and guide precision medicine in bladder cancer

BACKGROUND: Depicting the heterogeneity and functional characteristics of the tumor microenvironment (TME) is necessary to achieve precision medicine for bladder cancer (BLCA). Although classical molecular subtypes effectively reflect TME heterogeneity and characteristics, their clinical application...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Jiao, Othmane, Belaydi, Yu, Anze, Li, Huihuang, Cai, Zhiyong, Chen, Xu, Ren, Wenbiao, Chen, Jinbo, Zu, Xiongbing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8627095/
https://www.ncbi.nlm.nih.gov/pubmed/34836536
http://dx.doi.org/10.1186/s12916-021-02163-6
_version_ 1784606787934093312
author Hu, Jiao
Othmane, Belaydi
Yu, Anze
Li, Huihuang
Cai, Zhiyong
Chen, Xu
Ren, Wenbiao
Chen, Jinbo
Zu, Xiongbing
author_facet Hu, Jiao
Othmane, Belaydi
Yu, Anze
Li, Huihuang
Cai, Zhiyong
Chen, Xu
Ren, Wenbiao
Chen, Jinbo
Zu, Xiongbing
author_sort Hu, Jiao
collection PubMed
description BACKGROUND: Depicting the heterogeneity and functional characteristics of the tumor microenvironment (TME) is necessary to achieve precision medicine for bladder cancer (BLCA). Although classical molecular subtypes effectively reflect TME heterogeneity and characteristics, their clinical application is limited by several issues. METHODS: In this study, we integrated the Xiangya cohort and multiple external BLCA cohorts to develop a novel 5-methylcytosine (5mC) regulator-mediated molecular subtype system and a corresponding quantitative indicator, the 5mC score. Unsupervised clustering was performed to identify novel 5mC regulator-mediated molecular subtypes. The principal component analysis was applied to calculate the 5mC score. Then, we correlated the 5mC clusters (5mC score) with classical molecular subtypes, immunophenotypes, clinical outcomes, and therapeutic opportunities in BLCA. Finally, we performed pancancer analyses on the 5mC score. RESULTS: Two 5mC clusters, including 5mC cluster 1 and cluster 2, were identified. These novel 5mC clusters (5mC score) could accurately predict classical molecular subtypes, immunophenotypes, prognosis, and therapeutic opportunities of BLCA. 5mC cluster 1 (high 5mC score) indicated a luminal subtype and noninflamed phenotype, characterized by lower anticancer immunity but better prognosis. Moreover, 5mC cluster 1 (high 5mC score) predicted low sensitivity to cancer immunotherapy, neoadjuvant chemotherapy, and radiotherapy, but high sensitivity to antiangiogenic therapy and targeted therapies, such as blocking the β-catenin, FGFR3, and PPAR-γ pathways. CONCLUSIONS: The novel 5mC regulator-based subtype system reflects many aspects of BLCA biology and provides new insights into precision medicine in BLCA. Furthermore, the 5mC score may be a generalizable predictor of immunotherapy response and prognosis in pancancers. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12916-021-02163-6.
format Online
Article
Text
id pubmed-8627095
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-86270952021-11-30 5mC regulator-mediated molecular subtypes depict the hallmarks of the tumor microenvironment and guide precision medicine in bladder cancer Hu, Jiao Othmane, Belaydi Yu, Anze Li, Huihuang Cai, Zhiyong Chen, Xu Ren, Wenbiao Chen, Jinbo Zu, Xiongbing BMC Med Research Article BACKGROUND: Depicting the heterogeneity and functional characteristics of the tumor microenvironment (TME) is necessary to achieve precision medicine for bladder cancer (BLCA). Although classical molecular subtypes effectively reflect TME heterogeneity and characteristics, their clinical application is limited by several issues. METHODS: In this study, we integrated the Xiangya cohort and multiple external BLCA cohorts to develop a novel 5-methylcytosine (5mC) regulator-mediated molecular subtype system and a corresponding quantitative indicator, the 5mC score. Unsupervised clustering was performed to identify novel 5mC regulator-mediated molecular subtypes. The principal component analysis was applied to calculate the 5mC score. Then, we correlated the 5mC clusters (5mC score) with classical molecular subtypes, immunophenotypes, clinical outcomes, and therapeutic opportunities in BLCA. Finally, we performed pancancer analyses on the 5mC score. RESULTS: Two 5mC clusters, including 5mC cluster 1 and cluster 2, were identified. These novel 5mC clusters (5mC score) could accurately predict classical molecular subtypes, immunophenotypes, prognosis, and therapeutic opportunities of BLCA. 5mC cluster 1 (high 5mC score) indicated a luminal subtype and noninflamed phenotype, characterized by lower anticancer immunity but better prognosis. Moreover, 5mC cluster 1 (high 5mC score) predicted low sensitivity to cancer immunotherapy, neoadjuvant chemotherapy, and radiotherapy, but high sensitivity to antiangiogenic therapy and targeted therapies, such as blocking the β-catenin, FGFR3, and PPAR-γ pathways. CONCLUSIONS: The novel 5mC regulator-based subtype system reflects many aspects of BLCA biology and provides new insights into precision medicine in BLCA. Furthermore, the 5mC score may be a generalizable predictor of immunotherapy response and prognosis in pancancers. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12916-021-02163-6. BioMed Central 2021-11-26 /pmc/articles/PMC8627095/ /pubmed/34836536 http://dx.doi.org/10.1186/s12916-021-02163-6 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Hu, Jiao
Othmane, Belaydi
Yu, Anze
Li, Huihuang
Cai, Zhiyong
Chen, Xu
Ren, Wenbiao
Chen, Jinbo
Zu, Xiongbing
5mC regulator-mediated molecular subtypes depict the hallmarks of the tumor microenvironment and guide precision medicine in bladder cancer
title 5mC regulator-mediated molecular subtypes depict the hallmarks of the tumor microenvironment and guide precision medicine in bladder cancer
title_full 5mC regulator-mediated molecular subtypes depict the hallmarks of the tumor microenvironment and guide precision medicine in bladder cancer
title_fullStr 5mC regulator-mediated molecular subtypes depict the hallmarks of the tumor microenvironment and guide precision medicine in bladder cancer
title_full_unstemmed 5mC regulator-mediated molecular subtypes depict the hallmarks of the tumor microenvironment and guide precision medicine in bladder cancer
title_short 5mC regulator-mediated molecular subtypes depict the hallmarks of the tumor microenvironment and guide precision medicine in bladder cancer
title_sort 5mc regulator-mediated molecular subtypes depict the hallmarks of the tumor microenvironment and guide precision medicine in bladder cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8627095/
https://www.ncbi.nlm.nih.gov/pubmed/34836536
http://dx.doi.org/10.1186/s12916-021-02163-6
work_keys_str_mv AT hujiao 5mcregulatormediatedmolecularsubtypesdepictthehallmarksofthetumormicroenvironmentandguideprecisionmedicineinbladdercancer
AT othmanebelaydi 5mcregulatormediatedmolecularsubtypesdepictthehallmarksofthetumormicroenvironmentandguideprecisionmedicineinbladdercancer
AT yuanze 5mcregulatormediatedmolecularsubtypesdepictthehallmarksofthetumormicroenvironmentandguideprecisionmedicineinbladdercancer
AT lihuihuang 5mcregulatormediatedmolecularsubtypesdepictthehallmarksofthetumormicroenvironmentandguideprecisionmedicineinbladdercancer
AT caizhiyong 5mcregulatormediatedmolecularsubtypesdepictthehallmarksofthetumormicroenvironmentandguideprecisionmedicineinbladdercancer
AT chenxu 5mcregulatormediatedmolecularsubtypesdepictthehallmarksofthetumormicroenvironmentandguideprecisionmedicineinbladdercancer
AT renwenbiao 5mcregulatormediatedmolecularsubtypesdepictthehallmarksofthetumormicroenvironmentandguideprecisionmedicineinbladdercancer
AT chenjinbo 5mcregulatormediatedmolecularsubtypesdepictthehallmarksofthetumormicroenvironmentandguideprecisionmedicineinbladdercancer
AT zuxiongbing 5mcregulatormediatedmolecularsubtypesdepictthehallmarksofthetumormicroenvironmentandguideprecisionmedicineinbladdercancer